Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Compare

539 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RYTM Analyst Ratings

Strong Buy

14 Buy

1 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Rhythm

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RYTM Stock 12 Month Forecast

Average Price Target

$108.67

▲(15.23% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $108.67 with a high forecast of $135.00 and a low forecast of $80.00. The average price target represents a 15.23% change from the last price of $94.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"$45","136":"$136","67.75":"$67.8","90.5":"$90.5","113.25":"$113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$108.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,67.75,90.5,113.25,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.3,91.8923076923077,95.48461538461538,99.07692307692308,102.66923076923077,106.26153846153846,109.85384615384615,113.44615384615385,117.03846153846153,120.63076923076923,124.22307692307692,127.81538461538462,131.40769230769232,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.3,89.86692307692307,91.43384615384615,93.00076923076924,94.56769230769231,96.13461538461539,97.70153846153846,99.26846153846154,100.83538461538461,102.40230769230769,103.96923076923076,105.53615384615385,107.10307692307693,{"y":108.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.3,87.66153846153846,87.02307692307691,86.38461538461539,85.74615384615385,85.1076923076923,84.46923076923076,83.83076923076923,83.1923076923077,82.55384615384615,81.91538461538461,81.27692307692308,80.63846153846154,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$135.00

Average Price Target$108.67

Lowest Price Target$80.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$80→$100

Buy

6.03%

Upside

Reiterated

08/07/25

Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. WainwrightRhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright

Seamus Fernandez

Guggenheim

$119→$120

Buy

27.24%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

Whitney Ijem

Canaccord Genuity

$105

Buy

11.33%

Upside

Reiterated

08/06/25

Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals

Faisal Khurshid

Leerink Partners

$102

Buy

8.15%

Upside

Reiterated

08/06/25

Leerink Partners Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

Jonathan Wolleben

Citizens JMP

$130→$135

Buy

43.14%

Upside

Reiterated

08/06/25

Rhythm Pharmaceuticals price target raised to $135 from $130 at Citizens JMPRhythm Pharmaceuticals price target raised to $135 from $130 at Citizens JMP

Leland Gershell

Oppenheimer

$110

Buy

16.64%

Upside

Reiterated

08/06/25

Analysts Are Bullish on Top Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS)

Derek Archila

Wells Fargo

$129

Buy

36.78%

Upside

Reiterated

08/05/25

Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating

Joseph Stringer

Needham

$95

Buy

0.73%

Upside

Reiterated

08/05/25

Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating

Phil Nadeau

TD Cowen

$85→$110

Buy

16.64%

Upside

Reiterated

08/05/25

Rhythm Pharmaceuticals (RYTM) PT Raised to $110 at TD CowenTD Cowen analyst Phil Nadeau raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $110.00 (from $85.00) while maintaining a Buy rating.

Tazeen Ahmad

Bank of America Securities

$109→$122

Buy

29.36%

Upside

Reiterated

08/05/25

Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Strong Sales and Promising Growth Prospects

Michael Ulz

Morgan Stanley

$100→$109

Buy

15.58%

Upside

Reiterated

08/05/25

Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan StanleyRhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley

Corinne Johnson

Goldman Sachs

$97

Buy

2.85%

Upside

Reiterated

07/18/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Rhythm Pharmaceuticals (NASDAQ: RYTM) and IQVIA Holdings (NYSE: IQV)We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Paul Matteis

Stifel Nicolaus

$94→$123

Buy

30.42%

Upside

Reiterated

07/09/25

Stifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Dennis Ding

Jefferies

$80

Buy

-15.17%

Downside

Initiated

06/04/25

Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Promising Pipeline and Strategic Developments

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$80→$100

Buy

6.03%

Upside

Reiterated

08/07/25

Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. WainwrightRhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright

Seamus Fernandez

Guggenheim

$119→$120

Buy

27.24%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

Whitney Ijem

Canaccord Genuity

$105

Buy

11.33%

Upside

Reiterated

08/06/25

Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals

Faisal Khurshid

Leerink Partners

$102

Buy

8.15%

Upside

Reiterated

08/06/25

Leerink Partners Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

Jonathan Wolleben

Citizens JMP

$130→$135

Buy

43.14%

Upside

Reiterated

08/06/25

Rhythm Pharmaceuticals price target raised to $135 from $130 at Citizens JMPRhythm Pharmaceuticals price target raised to $135 from $130 at Citizens JMP

Leland Gershell

Oppenheimer

$110

Buy

16.64%

Upside

Reiterated

08/06/25

Analysts Are Bullish on Top Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS)

Derek Archila

Wells Fargo

$129

Buy

36.78%

Upside

Reiterated

08/05/25

Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating

Joseph Stringer

Needham

$95

Buy

0.73%

Upside

Reiterated

08/05/25

Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating

Phil Nadeau

TD Cowen

$85→$110

Buy

16.64%

Upside

Reiterated

08/05/25

Tazeen Ahmad

Bank of America Securities

$109→$122

Buy

29.36%

Upside

Reiterated

08/05/25

Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Strong Sales and Promising Growth Prospects

Michael Ulz

Morgan Stanley

$100→$109

Buy

15.58%

Upside

Reiterated

08/05/25

Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan StanleyRhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley

Corinne Johnson

Goldman Sachs

$97

Buy

2.85%

Upside

Reiterated

07/18/25

Paul Matteis

Stifel Nicolaus

$94→$123

Buy

30.42%

Upside

Reiterated

07/09/25

Stifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Dennis Ding

Jefferies

$80

Buy

-15.17%

Downside

Initiated

06/04/25

Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Promising Pipeline and Strategic Developments

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rhythm Pharmaceuticals

1 Month

xxx

Success Rate

15/18 ratings generated profit

Average Return

+8.08%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 83.33% of your transactions generating a profit, with an average return of +8.08% per trade.

3 Months

xxx

Success Rate

15/18 ratings generated profit

Average Return

+19.74%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +19.74% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

18/18 ratings generated profit

Average Return

+74.82%

reiterated a buy rating 7 days ago

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.82% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+158.16%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +158.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYTM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RYTM has received 37 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 108.67.

Each month's total comprises the sum of three months' worth of ratings.

RYTM Financial Forecast

RYTM Earnings Forecast

Next quarter’s earnings estimate for RYTM is -$0.69 with a range of -$0.86 to -$0.51. The previous quarter’s EPS was -$0.75. RYTM beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.34% of the time in the same period. In the last calendar year RYTM has Outperformed its overall industry.

RYTM Sales Forecast

Next quarter’s sales forecast for RYTM is $50.70M with a range of $46.00M to $53.35M. The previous quarter’s sales results were $48.50M. RYTM beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.74% of the time in the same period. In the last calendar year RYTM has Outperformed its overall industry.

RYTM Stock Forecast FAQ

What is RYTM’s average 12-month price target, according to analysts?

Based on analyst ratings, Rhythm Pharmaceuticals Inc’s 12-month average price target is 108.67.

What is RYTM’s upside potential, based on the analysts’ average price target?

Rhythm Pharmaceuticals Inc has 15.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RYTM a Buy, Sell or Hold?

Rhythm Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.

What is Rhythm Pharmaceuticals Inc’s price target?

The average price target for Rhythm Pharmaceuticals Inc is 108.67. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $80.00. The average price target represents 15.23% Increase from the current price of $94.31.

What do analysts say about Rhythm Pharmaceuticals Inc?

Rhythm Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of RYTM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

RYTM Analyst Ratings

RYTM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rhythm Pharmaceuticals

RYTM Analyst Recommendation Trends

RYTM Financial Forecast

RYTM Earnings Forecast

RYTM Sales Forecast

RYTM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts